Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study.

ABSTRACT:

Background

Beyond demographic and immune factors, metabolic considerations, particularly metformin's recognized impact in oncology, warrant exploration in treating pancreatic cancer. This study aimed to investigate the influence of metformin on patient survival and its potential correlation with distinct immune profiles in pancreatic ductal adenocarcinoma (PDAC) tumors.

Methods

We included 82 upfront resected and 66 gemcitabine-based neoadjuvant chemoradiotherapy (nCRT)-treated patients from the PREOPANC randomized controlled trial (RCT). Transcriptomic NanoString immunoprofiling was performed for a subset of 96 available resected specimens.

Results

Disparities in survival outcomes and immune profiles were apparent between metformin and non-metformin users in upfront

SUBMITTER: van Eijck CWF 

PROVIDER: S-EPMC11308183 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature